aceA multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
Background: Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor therapy, may improve survival in such recurrent cases. Previously evaluated predictors, including the International Association for the Study of Lung Cancer (IASLC) grading system applied to histol…
Combining routine histology slides with a transcriptomic score predicted 1-year recurrence more accurately than either source alone, across two independent validation cohorts.
PATH-ORACLE is currently a prognostic biomarker; extensive validation is still required before it can serve as a predictive biomarker for choosing adjuvant therapy.
Evidence
- Peer-reviewedImmuno-Oncology and Technology2026-09-17
How should this claim be treated?
Truvace Impact Record TRV-2026-1585, v1: “A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.” Truvace, 2026-10-16. /record/TRV-2026-1585 (accessed at citation time). sha256 dd16cabad881acc4…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1585 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.